Thank thanks the guidance and coronavirus. discuss of Today, you, joining XXXX Michaella. our afternoon, provide we Good everyone and will call. for impact our
path. we progress and this review on our will We mission made the company's have
financials then strategic to look roadmaps value we share for economic answering will our your propositions, review and our and We questions. forward clinical,
Please that on investor view go presentation slides there either the or on shared, to our call. we this is website webcast. Michaella As website our download referring be to to will our on an
investors. customers for of Let as coronavirus it top is team, me start our with a and mind comment on
monitoring to to this actively even scenario forward highly prolong. need should sheet, to the resources the intend want need capital are in deploy a we of though We balance the to that time fortified balance We business ongoing of our preserving mindful and we are drive thoughtfully uncertainty. We situation have planning. while stress
Where not we are today or to we XXXX to markets in intend go do public XXXX.
to Our to goal aspirational XXXX. is be for able sustain
will Our moment. be a more our achieve dependent evolves. how goals business ability these I'll on on to guidance in detail provide just
with and are we We now year the foundation. have full second believe the company a solid in built
can't. clear, improve is others to and treat what Our mission
track ablative valuable unique or growing. MRIdian Clinical high and in in ability to need therapy tumors the customers' interest patients that in ability desire. doses tissues safely The and real fewer fractions is five deliver combined to in time soft with is
XXXX been use demonstrated MRIdian's We its in journals of peer review merits documented in clinical have have now XXXs and patients and abstracts.
significant systems our across demonstrated have installations improvements market. operations and have capability We in now the and XX
of of five the or dose example post customers We one all have treating high several SBRT A the out day weeks per is several was training around effort patients Munich to gate. via treated commissioning, MRIdian. the also leverage full set in capability fewer recent right patient quickly In first fractions. exerted but
tumor and significant complications. not type lungs Clinically could be of high operationally, by to lung. of site his previously as making another on treated these treated not This having risk One despite lost system successfully shared us continue. the big damage strides are system. that progress with majority was through been comparable contralateral The lung a cause we typically and any radiation patients have treated will would the patient's would
market vetted On our in this indicator. is drive this true, remains will that This indicators believe we but near-term that shared the a leading important provide metric we orders. lagging have We therapy recognize most call will is adoption. we
We economic value will our propositions. into strategic work and of voice market clinical, this breakdown
guidance. XXXX discuss first Let's
we you'll we we accelerate raised December As when to capital the shared expect in recall, in that near-term. our did backlog not
on be see to $XX expect in in we X of $XX Slide cash million $XX range to million revenue range to XXXX the and used the of can $XX You million. be to million
Let me this provide context guidance. some on
Most notably in there the is uncertainty near-term. around coronavirus
today and are operational commercial impacted unfolds. activities depending how further Our impacted being and situation the maybe
cannot plant predict will We and other regions installations that plant hold restrictions projects place. in have XXXX in in have resume when when commence. installations nine the travel currently on will We
Teammate We priority are on a daily. unknown. Department the other is State monitoring the XXXX impact and sources very CDC, full simply coronavirus top following and is and safety carefully situation of
We As of revenue. QX. recognized today in approximately just in left two $XX million over weeks we have
one scheduled month We that this an area to which is affected be have to system could additional ship delayed.
orders have two We in received MRIdian far QX. thus
our situation As activities. impacting previously is shared, commercial the
to have We is not cancelations to our had inhibiting ability conduct situation business. coronavirus, order due but any the
and postponed ASTRO conferences key longer are allowing [ph] many visits several no example, and their are RSS For access. site just hospitals and accounts limiting
are relative we the beyond industry and have believe to built the coronavirus capabilities uncertainty, trends. we we in As confident look we are well-positioned
paradigm in the form lies primarily of treatment IMRT current therapy. The
While high-dose of many way relatively XXX% some centers feedback, XX% bundled the MRIdian SBRT of Customer SBRT time. payments, Advanced capable to for and form, the need data with the conventional approximately centers treat to treat utilize small this of are they demonstrating due percentage machines. patients systems. clinical in SBRT a limitations in
with work in that and Our customer survey fractions. doses high indicate fewer interactions treat to customers desire market
very are We for these trends. well-positioned
balance tissue. effective risk need drives XXX at dose favorable to and The is nontrivial. BEDXX risk. to outcomes, of healthy toxicity systems limitations more yet healthy that the ablative and the for protecting are an while ablative tissues tumor grade that XX coalitions ability organs dose versus doses ablative technology coverage the of Conventional doses conventional or to limit Evidence deliver biological demonstrates
And beam soft our automatic tissue compromise imaging These real-time Again, Real-time no to markets. a these capabilities gating. enables the market. of solution. represents provides limitations for compromise allows to stand enables in to is which stark reduce deliver solution features which that ablative aggregate a real-time the tracking offers and MRIdian the confidence adaptation contrast tighter MRIdian treatment doses effect of differentiated no avoid in treatment margins The toxicity.
intend by the proof. We leading with misinformation rise in and above industry clinical to the noise
We dictates are working enough good prove that medtech good large to is other definitive the not data of segments In clinical enough. landscape, therapy.
that randomized this Key doses goal tissue Our via leaders market. while oncology move data the the ablative is healthy separate in to MRIdian space that space. future radiation believe delivering opinion of preserving prospective, the is will
future. the is MRIdian such As
volumes. margins Take for treatment and example tumor
the plans are overlaid MRIdian. plan comparison. for MRI On Both the on left is right is an a treatment on market-leading CT LINAC and image
you mm. while On the tumor XX see a of right, margins to result of MRIdian. X to conventional would this XX in has sized on XX% reasonably X In approximately less treatment volume mm margins treatment MRIdian
to terms a plan a dose ball. in organs of the the to the plan is volume mm volume, tumor the tissues. think the treatment golf even conventional the for, tumor Conventional accounted of target movement simply for cannot size to tumor handcuffed If at clinicians XX doses. be motion treating the the increases that added dynamic In motion. of full the and in larger the size tumor ball. tennis to margin low The a however, is are that treatment the larger frequently a for simple MRIdian just create of healthy presence risk risk organ cannot and to account escalate of gives thus and LINAC of confidence to
of data the clinical comprehensive MRIdian's been I the clinical compendium MRIdian, work. will a done signal intend on data we and a how has do has led now that our to proof. share it to clinical compelling work context yielded, recorded and customers is of has deeper strong build
few past month. notable this just samples a from share me Let
paper reductions a cancer Washington on fractions to XX highlighted because treatment treatment reporting Journal University Red clinical single paper of enabled accepted on had of lumpectomy. prospective a after APBI treatment time margins. treatment down MRIdian results breast tight the from single-dose a for in trial The
a less post authors for more toxic the patients feasible convenient, "provides state, As surgery." breast option cancer MRIdian and
MR Lastly, as publication demonstrated large the with lung "practice low MRIdian patients high-dose the therapy dose high treated on guided SBRT Journal precise and high qualification changing series AUMC's of Red a technology Journal risk Lancet with Another delivery a in cancer liver allows complex that of resulting elsewhere." from identified for in Oncology toxicity.
The work toxicity, local maintaining understanding data deeper breadth importance to BED of quality in life. has while reducing XX or of of led clinical and healthy clarity this the and improving tissue, ablative doses control, delivering preserving
central doses the one report treat, pancreas, In to difficult up we Oligomet can toxicity see X X in therapy again demonstrated safe therapy significantly you the liver conventional than On demonstration XX%. grade of on we MRIdian to reports reports cancers is XX%. conventional over lower in toxicity toxicity while lung. most The ablative Slide with conventional and in X report of grade again technology. while X data X, Similarly,
A competitor that do XX% story. they can of different do, is evidence a often not but demonstrates enough we enough. says Good what good can
almost tumor all no enable "some This I are Our to of doses prescribe doses. Dr. in shared not or with the of with the recently horribly toxicity all hand be to to they instances. able coverage essence that giving tumor is potentially our the ablative or toxicity." major and all clinicians be treat might may the but Dr. am how still features captures of dose, other safe but most ablative MRIdian combination value low. some doses high the the quote Chuong very cause ViewRay. to allows mitigated, of ablative Chuong on target nearly
XX Slide to roadmap. Turning our for clinical
as initiated reduce open all delivering lung, prospective prove these trials X Building doses to can't, at data liver. what more existing than have and of is with reducing upon Oligomets ablative improve X toxicity Phase outcomes. XX in the central power projects goal XX such physician others pancreas, to that alone, technology our safely collaborators areas and our We projects, in clinical multicenter and and prostate, several XXXX while toxicity Phase pointed
new analyses, more. Included are plan indications studies, in of measures, quality-of-life and head-to-head cost-effectiveness this feasibility
process MRIdian and short-term longer-term strategic the of as to with are definitively roadmap We of follow-up the this a working out choice. partner treatment position in to for intended build evidence
paradigm strategy and of such to improve to capabilities, highlighted. as combined definitive the I've cancers data, prostate us We will ubiquitous incorporates difficult our and believe includes breast change also cancers care. that treat Our and clinical enable with more
As economic clinical to evidence, we and intend we value augment of the proof of pursue MRIdian. additional strategic
patients benefits cancer programs. today, share on they and As it added MRIdian provides to many untreatable systems. economic that are stands strategic be treating that would Customers other
Additionally, side for MRIdian. to that of therapy. differentiation operational treatment Between travel their customers shorter efficiencies due system effects of patients the to and drive share our strategic and patients courses fewer [ph]
real to XX customers. sites their we value to customers feedback, year. to equates share believe patients. value customer to economic add to over the our on the more XXXX may clinical definitive Based of program our develop to with their we approximately economic and new course In This proof patients intend
an system. adaptive say average, patient's The conventional our highlight on the X.X treatments patient take economic in times XX of the the how prostate XX and minutes see SBRT. X fractions two economic On value disruptive with to total MRIdian. XX benefits time fractions. the to table on X.X treat of that XXX XX increase treatments about patient Traditional majority table Slide IMRT between versus to If treatments example and each XX to able of the of minutes, high-dose and on being only potential to throughput efficiency fraction This minutes. you the be the the are treat is XXX in that Let's of throughput and nothing life. require X of XXX customers is can a between takes is patient a including
terms our Turning will is the clear to improve economic Slide positioning Customer XX. feedback further win to marketplace. in in of what
treatment asking times. workflow First, to simplify customers are reduce and us
minute Our in fractions in timeframe XX low-end and goal their is version of less prostate. sophisticated This the to is breast reach competitors at deliver of how sub SBRT.
guided for Japan Second, European and in the we countries. on Elekta are U.S., select with appropriate MR technology higher reimbursement working
are alternative methods MRIdian. Third, acquiring of we offering customers
by goods front. this believe on the over years efforts our We drive million flexibility next dollars for value will in to will economic enhance reduce combination of $X of cost customers. our three our these the We
in moving economic of our signs strategic clinical, customers. propositions with resonate and early positive seeing as are market the value We
early last built. of to in we team the year, was have programs in competitive of up accounts in to Florida, pipeline. is hundred In have are process. prospects pressures commercial and added our due the several of our MRIdian U.S. clusters new that Since many in our running stages The cycle of sales accounts we've these QX likely Northeast
what vetted have we XX, market will Slide it take MRIdian. the on to summary, In to move
to and on propositions therapy clarity have strategic We our adoption. value drive clinical, economic
paradigm we to to time the the working At forward need lead planning intend while improve scenario we We clinical of time to with balance drive the to actively preserving As we highlighted, and care. of will the same business monitoring uncertainty. work data are way as capital mitigate coronavirus. impact in this the of our
As XXXX. earlier, intend the do go or public shared XXXX we to markets in I not to
goal aspirational to say be the on for business but Our evolves. will XXXX, is same to dependent able be how this our
we We in situation and ability dependent on XXXX hospitals. excellence with performance gain are a the focused access highly is dynamic to control. upon obviously we things are and to executing our on travel
forward. have this designed focused Beyond value year are roadmaps to we we highlighted steady executing and growth going on yield creation the on
on to patients behalf motivated and shareholders. highly is team Our of deliver
to over Michaella. turn it that, With I'll
